go777 vegas slot
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform TM drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of 2025. Under the terms of the funding agreement, Serina will issue one million shares of common stock at $10 per share, a 120% premium to the closing price on November 26, 2024. The financing will be delivered in two tranches: the first $5.0 million tranche was received November 27, 2024, and the second $5.0 million tranche by January 31, 2025. Serina filed a Form 8-K with the SEC on December 2, 2024 that provides additional information regarding this transaction. About SER-252 (POZ-apomorphine) SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) and enable greater on time, with reduced off time, in advanced Parkinson’s patients. SER-252 leverages strategic partner Enable Injections’ enFuse TM wearable drug delivery platform to enhance patient comfort and convenience, providing CDS to patients via an easy-to-administer, long-acting subcutaneous injection without skin reactions. About the POZ Platform TM Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations. About Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform TM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatherapeutics.com . Cautionary Statement Regarding Forward-Looking Statement This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2023, the company’s Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and the company’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. For inquiries, please contact: Investor.relations@serinatherapeutics.com (256) 327-9630Stellantis lithium-sulfur EV batteries: cheaper, lighter, more range
The condemnation came as the House of Lords debated regulations paving the way for a scheme which would require animal lovers on the British mainland to have documentation in order to visit Northern Ireland. Critics view the move as further evidence of Northern Ireland still having to follow EU rules post-Brexit and being treated differently from the rest of the UK – a major source of contention to the unionist community. The paperwork, which will be free to apply for, includes a declaration that the owner will not travel onwards to Ireland or another EU country with their pet or assistance dog. Animals will have to be microchipped and have their own individual pet travel document, which will be valid for its lifetime. Northern Ireland residents returning after a stay in Great Britain with their pet or assistance dog will not need a travel document. The scheme is being introduced under the Windsor Framework, a revised deal for Northern Ireland’s post-Brexit trading arrangements aimed at tackling issues caused by the protocol. Raising her concerns in Parliament, Baroness Hoey, a Northern Irish Brexit supporter and former Labour MP, said: “These regulations are in effect about a new aspect of the Irish Sea border that has not had expression until this point because of the grace periods.” She added: “The experience of visiting Northern Ireland with your pet dog or cat, or even a ferret, will be made to feel like a visit to a foreign country. Lady Hoey went on: “This could spell the end of holiday trips for pet owners from GB to NI and then on to the Republic, when they want to explore both Northern Ireland and the Republic. “If they have a pet passport, they will have renounced their right to go to the Republic. That makes the border more of an obstruction than having border control posts on it, because at least in that eventuality, you could still cross over it.” Rejecting claims it was a result of the UK leaving the EU, she said: “The reality is that this is happening precisely because Northern Ireland has not got Brexit. “As we say repeatedly, it is still subject to EU rules and the EU could change the rules overnight.” Former DUP deputy leader Lord Dodds of Duncairn said: “Every one of the statutory instruments that come forward under the Windsor Framework must be properly debated, because these laws are being brought forward to implement what a foreign jurisdiction has decided should be the law of the United Kingdom. “In the 21st century, we should not accept colonial rule. We abolished it elsewhere. We believe it should not be tolerated for one second. People should have the democratic right to decide their laws for themselves, in their interests.” He added: “The ridiculous part about this debate is that we are having to debate European laws regulating the movement of pet animals owned by British citizens between one part of the United Kingdom and another. That is an outrage.” Lord Dodds went on: “As I said, there will be hundreds, thousands more of these regulations, in all areas, affecting the daily lives of people in Northern Ireland. They all add up to a grievous assault on Northern Ireland’s constitutional position.” But former leader of the Social Democratic and Labour Party (SDLP) Baroness Ritchie of Downpatrick said: “I support the Windsor Framework because it is a necessary legal device to deal with the complexities that were presented to us in Ireland, north and south, on the issue of Brexit. “We need a pragmatic solution rather than choosing to have political contests and duels simply for the sake of them.” Introducing the regulations, environment minister Baroness Hayman of Ulloch said: “This scheme will simplify the requirements associated with moving pet dogs, cats and ferrets from Great Britain to Northern Ireland significantly. “It replaces single-use animal health certificates with a free-of-charge lifelong travel document and removes the need for costly pet health treatments. “Pet owners who travel frequently with their pets, or those who rely on the services of an assistance dog to travel independently, will benefit substantially from this change in approach.” However, she acknowledged the concerns raised by peers and promised to continue engagement with them.
CARSON, Calif. (AP) — The LA Galaxy and the New York Red Bulls have been Major League Soccer mainstays since the league's inaugural season in 1996, signing glamorous players and regularly competing for championships through years of success and setbacks in a league that's perpetually improving and expanding. Yet just a year ago, both of these clubs appeared to be a very long way from the stage they'll share Saturday in the MLS Cup Final . The Galaxy were one of MLS’ worst teams after a season of internal turmoil and public fan dissent, while the Red Bulls were merely a steady mediocrity seeking yet another coach to chart a new direction. A year later, these MLS founders are meeting in the league's first Cup final between teams from North America's two biggest markets. “Two original clubs being able to put themselves in this situation, I think it’s great,” Galaxy coach Greg Vanney said. “To see two clubs that have been at it as long as this league has been around be here, I think it’s a special moment. Couldn’t be two more different and contrasting styles as well, which could make for an interesting game, and I would imagine a high-intensity game.” Everything changed in 2024 after a dismal decade for the Galaxy , who are favored to cap their transformation by winning their team's record sixth MLS championship with a roster that's dramatically different from its past few groups — albeit with one massive injury absence in the final. The transformation of the Red Bulls happened only in the postseason, when a team that hadn't won a playoff game since 2017 suddenly turned into world-beaters under rookie coach Sandro Schwarz. New York struggled through the final three months of league play with only two wins before posting road playoff victories over defending champ Columbus , archrival New York City FC and conference finalist Orlando to storm into the Cup final. “We know about the history (of our club), and we know tomorrow will define what that could mean,” Schwarz said Friday. “To feel the pressure for tomorrow, it’s necessary, because it’s a final, and without pressure it’s not possible to bring the best quality on the field.” The Red Bulls have never won an MLS Cup, only reaching the championship match once before. What's more, they've somehow never won a Cup in any tournament, although they’ve collected three Supporters’ Shields for MLS' best regular-season record. The Galaxy’s trophy case is large and loaded, and those five MLS Cups are on the top shelf. But not much of that team success happened in the past decade for the club that famously brought David Beckham, Zlatan Ibrahimovic, Robbie Keane, Steven Gerrard and many other international stars to Hollywood. In fact, this season has ended a grim era for the Galaxy, who haven't lost all year at their frequently renamed home stadium — which was the site of protests and boycotts just a year ago. The club's fans were tired of LA's steady underachievement and ineptitude in the front office run by team president Chris Klein, who was fired in May 2023. One year ago Thursday, the Galaxy hired Will Kuntz, a longtime Los Angeles FC executive who engineered his new club's roster transformation, most dramatically by landing new designated players Gabriel Pec and Joseph Paintsil — two international talents that LAFC also had in its sights. “I give Will and the group up there a ton of credit,” Vanney said. “It’s one thing to have players you like, and it’s a whole other thing to get them here and get them to connect with your group.” Pec and Paintsil combined for 32 goals and 27 assists while boosting the incumbent talents of striker Dejan Joveljic and Riqui Puig, the gifted Barcelona product who runs the offense from the midfield. The Galaxy clicked in the postseason, scoring a jaw-dropping 16 goals in four matches. Puig has been the Galaxy's most important player all season, but he won't be in the MLS Cup Final after tearing a knee ligament late in last week's conference final victory over Seattle . The loss of Puig — who somehow kept playing on his injured knee, and even delivered the game-winning pass to Joveljic — makes the Galaxy even more difficult to anticipate. “He played a lot in the regular season, so it was not so easy to analyze all these games now without him,” Schwarz said. “But the main focus is to analyze what we need to do, because it’s not clear now how they’re playing without him.” The Galaxy could give some of Puig's responsibilities to Marco Reus, the longtime Dortmund standout who joined LA in August. Reus is nursing a hamstring injury, but Vanney expects him to play. AP soccer: https://apnews.com/soccer
Rockridge Files Management Information Circular for Annual General and Special Meeting of Shareholders to Approve Business Combination with Eros Resources and MAS Gold
Signing with Dodgers was really easy decision for 2-time Cy Young winner Blake SnellLions should reunite with $9 million wide receiver to bolster offense | Sporting NewsSpanish Standings